Niacin
- Generic Name
- Niacin
- Brand Names
- Advicor, Concept Ob, Irospan 24/6 Kit, Mvc-fluoride, Niacor, Niaspan, Niodan, Simcor, Vitafol-one
- Drug Type
- Small Molecule
- Chemical Formula
- C6H5NO2
- CAS Number
- 59-67-6
- Unique Ingredient Identifier
- 2679MF687A
- Background
Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.
- Indication
Niacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injections. Niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemia. It can also be used to reduce the risk of nonfatal myocardial infarctions in patients with a history of myocardial infarction and hyperlipidemia. Niacin is also indicated with bile acid binding resins to treat atherosclerosis in patients with coronary artery disease and hyperlipidemia or to treat primary hyperlipidemia. Finally niacin is indicated to treat severe hypertriglyceridemia.
- Associated Conditions
- Atherosclerosis, High Cholesterol, High Triglyceride Level, Mixed Dyslipidemias, Nonfatal Myocardial Infarction, Pellagra, Primary Hypercholesterolemia, Severe Hypertriglyceridemia (sHTG), Type II Hyperlipidaemia
- Associated Therapies
- Dietary supplementation
Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2382
- Registration Number
- NCT06858332
Stimulating Fat Tissue Storage with Niacin to Reduce Fat Accumulation in the Liver.
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)Liver Fibrosis/NASHNon-Alcoholic Steato-Hepatitis (NASH)
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Université de Sherbrooke
- Target Recruit Count
- 36
- Registration Number
- NCT06843148
- Locations
- 🇨🇦
Centre de recherche du CHUS, Sherbrooke, Quebec, Canada
Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS)
- Conditions
- IBS - Irritable Bowel Syndrome
- Interventions
- First Posted Date
- 2025-01-07
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 10
- Registration Number
- NCT06760533
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
Nicotinic Acid for the Treatment of Alzheimer's Disease: a Phase 1b/2a Study
- Conditions
- Alzheimer Disease
- Interventions
- Drug: Placebo Comparator
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 30
- Registration Number
- NCT06582706
- Locations
- 🇺🇸
IU Health Neuroscience Center, Indianapolis, Indiana, United States
Psilocybin-assisted Therapy for Alcohol Use Disorder
- Conditions
- Alcohol Use DisorderAlcohol DependenceDepressionAnxiety
- Interventions
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- University of Sydney
- Target Recruit Count
- 90
- Registration Number
- NCT06444243
Study the Effect of Niacin on Lipoprotein (a) Concentration and Hyperphosphatemia in Hemodialysis Patients
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Al-Azhar University
- Target Recruit Count
- 50
- Registration Number
- NCT06406140
- Locations
- 🇪🇬
Al Azhar University, Cairo, Egypt
A Study of Niacin Regulation
- First Posted Date
- 2023-12-18
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 32
- Registration Number
- NCT06175403
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Adipose Tissue Storage in the Rapid Remission of Hepatic and Cardiac Metabolic Dysfunction After Bariatric Surgery
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Procedure: Bariatric surgery
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Université de Sherbrooke
- Target Recruit Count
- 40
- Registration Number
- NCT05934409
- Locations
- 🇨🇦
centre de recherche du CHUS, Sherbrooke, Quebec, Canada
MDMA-assisted Prolonged Exposure Therapy for Comorbid Alcohol Use Disorder and Post-traumatic Stress Disorder
- Conditions
- Post-traumatic Stress DisorderPTSDAlcohol Use DisorderAlcohol DependenceComorbidities and Coexisting Conditions
- Interventions
- First Posted Date
- 2023-02-02
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- University of Sydney
- Target Recruit Count
- 120
- Registration Number
- NCT05709353
- Locations
- 🇦🇺
Turning Point, Richmond, Victoria, Australia
🇦🇺Drug Health Services, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 66
- Registration Number
- NCT05452772
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Sheppard Pratt, Baltimore, Maryland, United States
🇺🇸Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.